164 related articles for article (PubMed ID: 27842893)
1. Identification of novel fluorescent probes preventing PrP
Zaccagnini L; Brogi S; Brindisi M; Gemma S; Chemi G; Legname G; Campiani G; Butini S
Eur J Med Chem; 2017 Feb; 127():859-873. PubMed ID: 27842893
[TBL] [Abstract][Full Text] [Related]
2. The compound (3-{5-[(2,5-dimethoxyphenyl)amino]-1,3,4-thiadiazolidin-2-yl}-5,8-methoxy-2H-chromen-2-one) inhibits the prion protein conversion from PrP
Pagadala NS; Bjorndahl TC; Joyce M; Wishart DS; Syed K; Landi A
Bioorg Med Chem; 2017 Oct; 25(20):5875-5888. PubMed ID: 28951092
[TBL] [Abstract][Full Text] [Related]
3. Strain-dependent profile of misfolded prion protein aggregates.
Morales R; Hu PP; Duran-Aniotz C; Moda F; Diaz-Espinoza R; Chen B; Bravo-Alegria J; Makarava N; Baskakov IV; Soto C
Sci Rep; 2016 Feb; 6():20526. PubMed ID: 26877167
[TBL] [Abstract][Full Text] [Related]
4. In silico studies and fluorescence binding assays of potential anti-prion compounds reveal an important binding site for prion inhibition from PrP(C) to PrP(Sc).
Pagadala NS; Perez-Pineiro R; Wishart DS; Tuszynski JA
Eur J Med Chem; 2015 Feb; 91():118-31. PubMed ID: 25042003
[TBL] [Abstract][Full Text] [Related]
5. Development of oligomeric prion-protein aggregates in a mouse model of prion disease.
Sasaki K; Minaki H; Iwaki T
J Pathol; 2009 Sep; 219(1):123-30. PubMed ID: 19479969
[TBL] [Abstract][Full Text] [Related]
6. In silico strategies on prion pathogenic conversion and inhibition from PrP
Pagadala NS; Syed K; Bhat R
Expert Opin Drug Discov; 2017 Mar; 12(3):241-248. PubMed ID: 28118747
[TBL] [Abstract][Full Text] [Related]
7. A Fluorescent Oligothiophene-Bis-Triazine ligand interacts with PrP fibrils and detects SDS-resistant oligomers in human prion diseases.
Imberdis T; Ayrolles-Torro A; Duarte Rodrigues A; Torrent J; Alvarez-Martinez MT; Kovacs GG; Verdier JM; Robitzer M; Perrier V
Mol Neurodegener; 2016 Jan; 11():11. PubMed ID: 26809712
[TBL] [Abstract][Full Text] [Related]
8. Molecular Mechanism of the Misfolding and Oligomerization of the Prion Protein: Current Understanding and Its Implications.
Singh J; Udgaonkar JB
Biochemistry; 2015 Jul; 54(29):4431-42. PubMed ID: 26171558
[TBL] [Abstract][Full Text] [Related]
9. Binding of disease-associated prion protein to plasminogen.
Fischer MB; Roeckl C; Parizek P; Schwarz HP; Aguzzi A
Nature; 2000 Nov; 408(6811):479-83. PubMed ID: 11100730
[TBL] [Abstract][Full Text] [Related]
10. A Small-Molecule Inhibitor of Prion Replication and Mutant Prion Protein Toxicity.
Massignan T; Sangiovanni V; Biggi S; Stincardini C; Elezgarai SR; Maietta G; Andreev IA; Ratmanova NK; Belov DS; Lukyanenko ER; Belov GM; Barreca ML; Altieri A; Kurkin AV; Biasini E
ChemMedChem; 2017 Aug; 12(16):1286-1292. PubMed ID: 28722340
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Novel Anti-prion Compounds Using In Silico and In Vitro Approaches.
Hyeon JW; Choi J; Kim SY; Govindaraj RG; Jam Hwang K; Lee YS; An SS; Lee MK; Joung JY; No KT; Lee J
Sci Rep; 2015 Oct; 5():14944. PubMed ID: 26449325
[TBL] [Abstract][Full Text] [Related]
12. Preventing misfolding of the prion protein by trimethylamine N-oxide.
Bennion BJ; DeMarco ML; Daggett V
Biochemistry; 2004 Oct; 43(41):12955-63. PubMed ID: 15476389
[TBL] [Abstract][Full Text] [Related]
13. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
[TBL] [Abstract][Full Text] [Related]
14. Prion Infectivity Plateaus and Conversion to Symptomatic Disease Originate from Falling Precursor Levels and Increased Levels of Oligomeric PrPSc Species.
Mays CE; van der Merwe J; Kim C; Haldiman T; McKenzie D; Safar JG; Westaway D
J Virol; 2015 Dec; 89(24):12418-26. PubMed ID: 26423957
[TBL] [Abstract][Full Text] [Related]
15. Breakage of PrP aggregates is essential for efficient autocatalytic propagation of misfolded prion protein.
Piening N; Weber P; Giese A; Kretzschmar H
Biochem Biophys Res Commun; 2005 Jan; 326(2):339-43. PubMed ID: 15582583
[TBL] [Abstract][Full Text] [Related]
16. Treatment of SMB-S15 Cells with Resveratrol Efficiently Removes the PrP(Sc) Accumulation In Vitro and Prion Infectivity In Vivo.
Wang J; Zhang BY; Zhang J; Xiao K; Chen LN; Wang H; Sun J; Shi Q; Dong XP
Mol Neurobiol; 2016 Oct; 53(8):5367-76. PubMed ID: 26440667
[TBL] [Abstract][Full Text] [Related]
17. Prion protein self-interactions: a gateway to novel therapeutic strategies?
Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
[TBL] [Abstract][Full Text] [Related]
18. Immunopurification of pathological prion protein aggregates.
Biasini E; Tapella L; Mantovani S; Stravalaci M; Gobbi M; Harris DA; Chiesa R
PLoS One; 2009 Nov; 4(11):e7816. PubMed ID: 19915706
[TBL] [Abstract][Full Text] [Related]
19. Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin.
Haviv Y; Avrahami D; Ovadia H; Ben-Hur T; Gabizon R; Sharon R
Arch Neurol; 2008 Jun; 65(6):762-75. PubMed ID: 18541796
[TBL] [Abstract][Full Text] [Related]
20. An improved method for cell-to-cell transmission of infectious prion.
Tanaka M; Hara H; Nishina H; Hanada K; Hagiwara K; Maehama T
Biochem Biophys Res Commun; 2010 Jul; 397(3):505-8. PubMed ID: 20515650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
